Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user looking at the ocean with an arm around his wife.
Potential OPDIVO® (nivolumab) user looking at the ocean with an arm around his wife.

Clinical trial results for
Stage 2B or Stage 2C
melanoma after surgery

To help prevent a type of skin cancer called
melanoma from coming back in certain people
with Stage IIB or Stage IIC melanoma after it has been completely removed by surgery

Actor portrayals.

An FDA-approved immunotherapy that may help reduce the risk of melanoma coming back after surgery compared to placebo

Having surgery was an important step for you to take in treating your cancer, but to make sure your cancer doesn't return, your doctor may recommend adjuvant therapy. This is a type of treatment used after surgery to help prevent cancer from coming back by making sure no hidden or hard-to-see cells are left after surgery.

About the clinical trial

In a clinical trial of 790 people who had their Stage 2B or 2C melanoma completely removed by surgery, 526 people were given OPDIVO and 264 people were given placebo.

More people did not have their melanoma return after surgery compared to
placebo at 1 year

At 12 months, 89% of those given OPDIVO® did not have their melanoma return after surgery, versus 79% given a placebo.

In the clinical trial, people given OPDIVO had a 58% lower risk of their melanoma returning after surgery than those given placebo.

OPDIVO will not work for everyone. Individual results may vary.

OPDIVO Qvantig may be a faster* way to receive treatment.

It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

Timer icon indicating the injection of OPDIVO® QVANTIG™ takes 3-5 minutes.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.

Getting treatment

See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)

For certain people to help prevent Stage IIB or Stage IIC melanoma from coming back after it has been completely removed by surgery

As an intravenous infusion

OPDIVO® (nivolumab) is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults and children 12 years and older with Stage IIB or Stage IIC melanoma to help prevent melanoma from coming back after it has been completely removed by surgery.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

As a subcutaneous injection

OPDIVO Qvantig (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults with Stage IIB or Stage IIC melanoma to help prevent melanoma from coming back after it has been completely removed by surgery.

It is not known if OPDIVO Qvantig is safe and effective in children.



466-US-2500015  03/25